Abstract 4967
Background
No data are available on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated BC pts.
Methods
A 26-item survey exploring fertility preservation and pregnancy after BC was emailed to physicians attending the 2016 3rd ESO-ESMO BCY3 and the 2017 15th St. Gallen BCC 2017 conferences. The present analysis investigated potential differences in physicians’ knowledge, attitudes and practice towards these issues in BC pts with or without BRCA mutations. The McNemar test for paired proportions was used for statistical comparison.
Results
The survey was completed by 273 physicians (105 at BCY3 and 168 at BCC 2017) with a median age of 46 years (range 38-55); the majority were medical oncologists (56%) practicing in an academic setting (86%). A comparable proportion of respondents suggested the use of either embryo (43% vs. 39%; p = 0.11) or oocyte (62% vs. 63%; p = 0.77) cryopreservation as available options for BC pts with or without BRCA mutations, respectively. Conversely, ovarian tissue cryopreservation (33% vs. 40%; p = 0.009) and GnRHa during chemotherapy (74% vs. 81%; p = 0.001) were less commonly suggested in BRCA-mutated BC pts than in BC pts without BRCA mutations. 42% agreed or were neutral on the statement that controlled ovarian stimulation should not be considered safe in BRCA-mutated BC pts. 45% and 30% agreed or were neutral on the statement that pregnancy in BC survivors may increase the risk of recurrence in BRCA-mutated BC pts and in BC pts overall, respectively (p < 0.001). 15% and 3% disagreed that transplanting the cryopreserved ovarian tissue harvested at the time of BC diagnosis can be considered safe in pts with or without BRCA mutations, respectively (p < 0.001).
Conclusions
These results highlight the presence of several misconceptions on fertility preservation and pregnancy after BC that persist even among physicians directly involved in BC care. Focused research efforts to address fertility and pregnancy-related issues in BRCA-mutated BC pts and education to improve physicianś knowledge and adherence to available guidelines are urgently needed.
Clinical trial identification
Legal entity responsible for the study
Matteo Lambertini.
Funding
Has not received any funding,
Editorial Acknowledgement
Disclosure
M. Lambertini: Support from the European Society for Medical Oncology (ESMO) for a Translational Research Fellowship at the Institut Jules Bordet (Brussels, Belgium). All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract